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ABSTRACT
This is the ﬁfth statistics note produced by the
Ophthalmic Statistics Group (OSG) which is designed to
be a simple guide to ophthalmic researchers on a
statistical issue with an applied ophthalmic example.
The OSG is a collaborative group of statisticians who
have come together with a desire to raise the statistical
standards of ophthalmic researcher by increasing
statistical awareness of common issues.
A typical question facing an ophthalmologist in
clinic is: ‘How good is a particular test at diagnosing
a particular pathology’? For example, how useful
are the results from a Visual Field Analyser (VFA) in
diagnosing glaucoma? Although a positive test result
can indicate the presence of a symptom, such as
visual ﬁeld loss, full clinical diagnosis of a disease or
condition is considerably more complicated. For
instance, in glaucoma, a full clinical examination
involving a battery of tests evaluating visual ﬁeld
loss, intraocular pressure, the optic nerve and func-
tional tests such as standard automated perimetry
are necessary to make a diagnosis.1 Performing each
test is costly and time consuming, and in some coun-
tries only a single test may be available for a particu-
lar condition. Where multiple tests are available, it is
desirable, therefore, to compare their performance
in a quantitative way through assessing their diag-
nostic utility and by examining the sensitivity and
speciﬁcity with their respective CIs.
Suppose, for example, I have 200 individuals
referred for assessment in my glaucoma clinic, 100
of the subjects referred are assessed using a VFA,
while the other 100 are assessed using a new
imaging technology. Individuals are classed as posi-
tive or negative according to whether their test
result is positive or negative. The positive and nega-
tive refer to presence of an abnormality in visual
ﬁeld or optic disc, rather than the outlook for the
patient, though it may seem perverse that a positive
test result actually translates to something which
might be viewed as negative news for the patient.
It may be tempting to assume from table 1 that
the VFA is more useful in the diagnosis of glaucoma
because it is identifying more subjects as positive.
However, this may not reﬂect the full picture as a
diagnostic test may not always give the correct
classiﬁcation. There are two types of error possible:
the ﬁrst type is when a healthy person is told that
they have the pathology, a false positive; while the
second type is when an individual with pathology is
not identiﬁed by the test, a false negative. A false
positive is essentially a false alarm, which could lead
to subjects being incorrectly referred, causing them
unnecessary anxiety and wasting clinical time and
resources, or worse still, in other pathologies, poten-
tially having to undergo unnecessary treatment if
the correct diagnosis is not made in the clinic. A
false negative can have equally dire consequences; if
a patient has the pathology but is not diagnosed,
then this would lead to them being falsely reassured
that all is well and not receiving appropriate treat-
ment at the earliest stage of their disease.
One approach to assessing the usefulness of a
test is to perform it in a number of patients with
known pathology, comparing the test results with
this diagnosis. In this example, we consider the
number of patients with known glaucoma who test
positively using the VFA test (table 2) or the new
imaging technology (table 3).
There are 25 subjects with known glaucoma and
75 subjects without the condition. The proportions
of these two groups correctly diagnosed by the
VFA were 24/25=0.96 and 57/75=0.76. These two
proportions are given similar sounding names and
are clearly described in a statistics note without
application to ophthalmology.2
Sensitivity is the proportion of subjects with a
diagnosis who are correctly identiﬁed by the test.
Sensitivity ¼
True Positives
All those with pathology
¼
True Positives
True Positivesþ FalseNegatives
¼
24
24þ 1
¼ 0:96
Table 1 Test results on 200 subjects
Test
Test
positive (+)
Test
negative (−) Total
VFA 42 58 100
Imaging technology 24 76 100
VFA, Visual Field Analyser.
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Speciﬁcity is the proportion of subjects without a diagnosis who
are correctly identiﬁed by the test.
Specificity ¼
True Negatives
All thosewithout pathology
¼
TrueNegatives
TrueNegativesþ False Positives
¼
57
57þ 18
¼ 0:76
We can say based on our test results that we expect 96% of
patients with glaucoma to have abnormal VFA results (test posi-
tive), while 76% of subjects without glaucoma would have
normal VFA results (test negative).
If we now consider the imaging technology, we have the fol-
lowing test results: of the 25 glaucoma patients, the imaging
technique detects 15 as positive. The sensitivity is therefore
15/25=0.60 (or 60%). Of the 75 subjects without glaucoma,
the imaging technique correctly identiﬁes 66. The imaging tech-
nique, therefore, has a speciﬁcity of 66/75=0.88 (or 88%).
The VFA has higher sensitivity (0.96 vs 0.60) and a lower
speciﬁcity (0.76 vs 0.88) than the imaging technique.
Sensitivity and speciﬁcity are proportions, so CIs can be calcu-
lated for them using standard methods.3 It is important to
ensure that the method adopted for calculating the CI is correct
for the type of sample that you have. One indication that this is
not the case would be when a CI exceeds 100%, which clearly
it can never do.4 5
If this is done for this scenario we obtain the results shown in
table 4.
When considering sensitivities and speciﬁcities it is also essen-
tial to consider the merits of the study used to provide these
estimates. Initiatives such as the STARD statement (STAndards
for the Reporting of Diagnostic accuracy studies)6 and
QUADAS7 (QUality Assessment of Diagnostic Accuracy Studies)
have been developed in order to aid experimenters and readers
to assess the internal and external validity of diagnostic studies,
and we would urge readers to look through these checklists to
optimise what can be established from these studies. For further
information on this topic, we would refer the interested reader
to other relevant articles.8 9
CHOOSING A TEST
So, which is the best test here? On the one hand, using the
more sensitive but less speciﬁc method (VFA in this ﬁctitious
example) will lead to more false positives and thus greater cost
and time burdens to clinics and more patients with undue
concern, while, on the other hand, using the more speciﬁc but
less sensitive method (imaging technology) will lead to more
false negatives, that is, more patients not being diagnosed, or
being diagnosed late on in the disease if the test is repeated.
Unsatisfactory as it may be, the answer is: it depends.
Consideration needs to be given to the consequences of being a
false positive or a false negative. If a false negative error is
serious, as would be the case if diagnosing ocular tumours, a
high sensitivity would take priority. If there is a need to avoid
false positives, as might be the case in the glaucoma example
and for other diseases with a low prevalence in the population,
then a high speciﬁcity would be desirable.
A positive test that has high sensitivity is not a guarantee that
the individual has the condition, particularly when speciﬁcity is
not very high and the condition in question is rare. For instance,
in our example scenario, which has a high prevalence of patients
with glaucoma (25%), the sensitivity of VFA is high (96%),
meaning that a high proportion of individuals with glaucoma
would be correctly referred (only 4% would be missed).
However, almost half of the positive tests overall are, in fact,
false positives (18/42=42.8%), which represents an unaccept-
ably large drain on resources in the context of glaucoma and
treatment of many other conditions. It is, therefore, important
to bear in mind that, in this context, a positive test requires
further conﬁrmation, while a negative test is more likely to be
correct because, with a highly sensitive test, there are few false
negative results, as seen in table 2. Indeed, if a test is 100% sen-
sitive, there will be no false negatives, so a negative test will
always be a true negative.
Obviously, it would be ideal for both sensitivity and speciﬁcity
to be high, a perfect test having 100% sensitivity and 100%
speciﬁcity, but, in practice, selecting the cut-off is always a com-
promise between sensitivity and speciﬁcity because there is gener-
ally a trade-off between the two; as one measure increases, the
other decreases. The cut-off selected to deﬁne a positive test for a
continuous testing method should be selected to optimise the
balance between sensitivity and speciﬁcity. For example, using
more stringent criteria for abnormal VFA results would decrease
the proportion of individuals wrongly classiﬁed as having glau-
coma, although it would also result in some patients who had cor-
rectly been classiﬁed with glaucoma now being misdiagnosed as
without the condition. In other words, for a given cut-off, the sen-
sitivity can be increased at the expense of speciﬁcity and vice
versa. When comparing two tests, it is a good practice to select
cut-offs that ﬁx speciﬁcity at a particular level for both tests, which
allows test sensitivities to be compared at equivalent speciﬁcities.
LESSONS LEARNED
▸ Sensitivity and speciﬁcity are useful summary measures for
describing the diagnostic utility of a testing method. Test
utility measures should be summarised using CIs.
Table 3 Imaging technology test results for subjects with known
glaucoma status
Test—Imaging technology
Glaucoma (true status)
Present Absent Total
Test positive 15
True positive
9
False positive
24
Test negative 10
False negative
66
True negative
76
25 75 100
Table 2 VFA test results for subjects with known glaucoma status
Test—VFA
Glaucoma (true status)
Present Absent Total
Test positive 24
True positive
18
False positive
42
Test negative 1
False negative
57
True negative
58
Total 25 75 100
VFA, Visual Field Analyser.
Table 4 95% CIs for estimates of sensitivity% and specificity%
VFA Imaging technology
Sensitivity 96% (88.3% to 100%) 60% (40.8% to 79.2%)
Specificity 76% (66.3% to 85.7%) 88% (80.6% to 95.4%)
VFA, Visual Field Analyser.
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▸ As a condition will usually have a low prevalence in the
population, a positive test result is likely to require independ-
ent conﬁrmation even when using a highly sensitive test,
while a negative ﬁnding is more likely to be truly negative.
▸ The cut-off used to deﬁne a positive test can be selected to
obtain an optimal compromise between sensitivity and speciﬁ-
city. A useful strategy for comparing diagnostic test perform-
ance is to compare sensitivities at equivalent speciﬁcities.
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